HC Wainwright reiterated their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a report released on Wednesday morning, Benzinga reports. The brokerage currently has a $3.00 target price on the stock. TransCode Therapeutics Stock Performance NASDAQ:RNAZ opened at $1.78 on Wednesday. The firm has a market cap of $11.75 million, a […]